MedTrace Logo

A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer

NCT00632541 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2018-02-14

Study results available
· View outcomes & findings →

Summary

Prior clinical trials involving bevacizumab and sorafenib have demonstrated single agent activity in previously treated advanced breast cancer. This trial will test combined VEGF inhibition with sorafenib and bevacizumab in less heavily pre-treated patients with advanced breast cancer.

Conditions

Interventions

DRUG

Sorafenib

Sorafenib 200mg po daily

DRUG

Bevacizumab

Bevacizumab 5mg/kg every other week 1 Cycle = 4 weeks

OTHER

Imaging

Imaging every third cycle

Sponsors & Collaborators

  • Hoosier Cancer Research Network

    lead OTHER

  • Genentech, Inc.

    collaborator INDUSTRY

  • Bayer

    collaborator INDUSTRY

  • Amgen

    collaborator INDUSTRY

Principal Investigators

  • Robin T Zon, M.D. · Hoosier Oncology Group, Inc.

  • Kathy Miller, M.D. · Hoosier Oncology Group, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2009-03-31
Completion
2009-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00632541 on ClinicalTrials.gov